Skip to Content

Vorinostat Dosage

Medically reviewed on August 6, 2018.

Applies to the following strengths: 100 mg

Usual Adult Dose for Cutaneous T-cell Lymphoma

400 mg orally once a day; If a patient is intolerant to therapy, the dose may be reduced to 300 mg orally once daily; the dose may be further reduced to 300 mg once daily for 5 consecutive days each week if needed

-This drug should be taken with food.
-Swallow capsules whole; do not open or crush.
-Therapy may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.

Use: For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent, or recurrent disease on or following 2 systemic therapies

Renal Dose Adjustments

Caution recommended.

Liver Dose Adjustments

-Mild to moderate hepatic impairment (bilirubin 1 to 3 times the upper limit of normal (ULN) or AST greater than ULN): Reduce the starting dose to 300 mg orally once daily
-Severe hepatic impairment (bilirubin greater than 3 x ULN): Data not available

Dose Adjustments

If a patient is intolerant to 400 mg once daily, the dose may be reduced to 300 mg orally once daily; the dose may be further reduced to 300 mg once daily for 5 consecutive days each week if needed.

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug should be taken with food.
-Swallow capsules whole; do not open or crush.
-Direct contact with the powder contained in the capsules with the skin or mucous membranes should be avoided. The area(s) should be washed thoroughly if contact occurs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide